Home › Therapeutic areas › Neurology › Generalized Anxiety Disorder
Generalized Anxiety Disorder (5 companies)
Companies with an active program in Generalized Anxiety Disorder.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ATAI | Atai Beckley | Neurology | 1 | Phase 2 | $2.73B | 5 |
| DFTX | Definium Therapeutics | Neurology | 1 | Phase 3 | $4.47B | 4 |
| HELP | Helus Pharma | Neurology | 1 | Phase 3 | $655M | 3 |
| IXHL | Incannex Healthcare | NeurologyRespiratory | 1 | Phase 2 | $28.1M | 2 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
No companies match.